Regulation of dolichol-linked glycosylation

Glycoconjugate Journal

Volumn 30, Issue 1, 2013, Pages 51-56

  Welti, Michael ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

CDG; Dolichol; Mevalonate pathway; Statins

Indexed keywords

3 [(3,3' BITHIOPHEN 5 YL)METHOXY] N (6,6 DIMETHYL 2 HEPTEN 4 YNYL) N ETHYLBENZYLAMINE; CLOFIBRATE; CYCLIC AMP; DOLICHOL; EPIGALLOCATECHIN GALLATE; FUCOSE; GLYCAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MANNOSE; MEVALONIC ACID; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOMEVALONATE KINASE; PRAVASTATIN; SQUALENE MONOOXYGENASE; SQUALENE SYNTHASE; STEROID 5ALPHA REDUCTASE 3; UNCLASSIFIED DRUG; ZARAGOZIC ACID A;

ARTICLE; CARBOHYDRATE SYNTHESIS; CLINICAL FEATURE; CONGENITAL DISORDER OF GLYCOSYLATION; DIET SUPPLEMENTATION; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; MEVALONIC ACIDURIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RETINITIS PIGMENTOSA;

CARBOHYDRATE SEQUENCE; CONGENITAL DISORDERS OF GLYCOSYLATION; DOLICHOL; DOLICHOL PHOSPHATES; GLYCOSYLATION; HUMANS; POLYSACCHARIDES;

EID: 84872676605     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-012-9417-y     Document Type: Article

References (54)

1. Schwarz, F., Aebi, M.: Mechanisms and principles of N-linked protein glycosylation. Curr. Opin. Struct. Biol. 21(5), 576-582 (2011)
2. Larkin, A., Imperiali, B.: The expanding horizons of asparagine-linked glycosylation. Biochemistry 50(21), 4411-4426 (2011)
3. Kornfeld, R., Kornfeld, S.: Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54, 631-664 (1985)
4. Swiezewska, E., Danikiewicz, W.: Polyisoprenoids: structure, biosynthesis and function. Prog. Lipid Res. 44(4), 235-258 (2005)
5. Buhaescu, I., Izzedine, H.: Mevalonate pathway: A review of clinical and therapeutical implications. Clin. Biochem. 40(9-10), 575-584 (2007)
6. Maeda, Y., Kinoshita, T.: Dolichol-phosphate mannose synthase: structure, function and regulation. Biochim. Biophys. Acta 1780(6), 861-868 (2008)
7. Heesen, S., et al.: Isolation of the ALG5 locus encoding the UDP-glucose:dolichyl-phosphate glucosyltransferase from Saccharomyces cerevisiae. Eur. J. Biochem. 224(1), 71-79 (1994)
8. Rush, J.S., et al.: Identification and characterization of a cDNA encoding a dolichyl pyrophosphate phosphatase located in the endoplasmic reticulum of mammalian cells. J. Biol. Chem. 277(47), 45226-45234 (2002)
9. Rush, J.S., et al.: Recycling of dolichyl monophosphate to the cytoplasmic leaflet of the endoplasmic reticulum after the cleavage of dolichyl pyrophosphate on the lumenal monolayer. J. Biol. Chem. 283(7), 4087-4093 (2008)
10. van Berkel, M.A., et al.: The Saccharomyces cerevisiae CWH8 gene is required for full levels of dolichol-linked oligosaccharides in the endoplasmic reticulum and for efficient N-glycosylation. Glycobiology 9(3), 243-253 (1999)
11. Cantagrel, V., Lefeber, D.J.: From glycosylation disorders to dolichol biosynthesis defects: A new class of metabolic diseases. J. Inherit. Metab. Dis. 34(4), 859-867 (2011)
12. Zelinger, L., et al.: A missense mutation in DHDDS, encoding dehydrodolichyl diphosphate synthase, is associated with autosomal-recessive retinitis pigmentosa in Ashkenazi Jews. Am. J. Hum. Genet. 88(2), 207-215 (2011)
13. Lefeber, D.J., et al.: Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS Genet. 7(12), e1002427 (2011)
14. Stoffels, M., Simon, A.: Hyper-IgD syndrome or mevalonate kinase deficiency. Curr. Opin. Rheumatol. 23(5), 419-423 (2011)
15. Goldfinger, S.: The inherited autoinflammatory syndrome: A decade of discovery. Trans. Am. Clin. Climatol. Assoc. 120, 413-418 (2009)
16. Drenth, J.P., Haagsma, C.J., van der Meer, J.W.: Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 73(3), 133-144 (1994)
17. Haas, D., Hoffmann, G.F.: Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J. Rare Dis. 1, 13 (2006)
18. Mandey, S.H., et al.: A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum. 54(11), 3690-3695 (2006)
19. Kuijk, L.M., et al.: Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol. Immunol. 45(8), 2158-2165 (2008)
20. Hoffmann, G.F., et al.: Regulatory adaptation of isoprenoid biosynthesis and the LDL receptor pathway in fibroblasts from patients with mevalonate kinase deficiency. Pediatr. Res. 41(4 Pt 1), 541-546 (1997)
21. Rosenberg, T.: Epidemiology of hereditary ocular disorders. Dev. Ophthalmol. 37, 16-33 (2003)
22. Fliesler, S.J., Rapp, L.M., Hollyfield, J.G.: Photoreceptor-specific degeneration caused by tunicamycin. Nature 311(5986), 575-577 (1984)
23. Fliesler, S.J., Rayborn, M.E., Hollyfield, J.G.: Membrane morphogenesis in retinal rod outer segments: inhibition by tunicamycin. J. Cell Biol. 100(2), 574-587 (1985)
24. Grunewald, S.: The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim. Biophys. Acta 1792(9), 827-834 (2009)
25. Cantagrel, V., et al.: SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 142(2), 203-217 (2010)
26. Kasapkara, C.S., et al.: SRD5A3-CDG: A patient with a novel mutation. Eur. J. Paediatr. Neurol. (2012)
27. Kranz, C., et al.: A defect in dolichol phosphate biosynthesis causes a new inherited disorder with death in early infancy. Am. J. Hum. Genet. 80(3), 433-440 (2007)
28. Michele, D.E., et al.: Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage. Circ. Res. 105(10), 984-993 (2009)
29. Dancourt, J., et al.: A new intronic mutation in the DPM1 gene is associated with a milder form of CDG Ie in two French siblings. Pediatr. Res. 59(6), 835-839 (2006)
30. Garcia-Silva, M.T., et al.: Congenital disorder of glycosylation (CDG) type Ie. A new patient. J. Inherit. Metab. Dis. 27(5), 591-600 (2004)
31. Imbach, T., et al.: Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie. J. Clin. Invest. 105(2), 233-239 (2000)
32. Kim, S., et al.: Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie). J. Clin. Invest. 105(2), 191-198 (2000)
33. Lefeber, D.J., et al.: Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am. J. Hum. Genet. 85(1), 76-86 (2009)
34. Niehues, R., et al.: Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J. Clin. Invest. 101(7), 1414-1420 (1998)
35. Westphal, V., et al.: Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type Ib: long-term outcome and effects of mannose supplementation. Mol. Genet. Metab. 73(1), 77-85 (2001)
36. Marquardt, T., et al.: Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 94(12), 3976-3985 (1999)
37. Haeuptle, M.A., et al.: Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid. J. Biol. Chem. 286(8), 6085-6091 (2011)
38. Forman, B.M., Chen, J., Evans, R.M.: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-Activated receptors alpha and delta. Proc. Natl. Acad. Sci. U. S. A. 94(9), 4312-4317 (1997)
39. Abourbih, S., et al.: Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review. Am. J. Med. 122(10), 962 e1-8 (2009)
40. Insel, P.A., Ostrom, R.S.: Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell. Mol. Neurobiol. 23(3), 305-314 (2003)
41. Konrad, M., Merz, W.E.: Regulation of N-glycosylation. Long term effect of cyclic AMP mediates enhanced synthesis of the dolichol pyrophosphate core oligosaccharide. J. Biol. Chem. 269(12), 8659-8666 (1994)
42. Konrad, M., Merz, W.E.: Long-term effect of cyclic AMP on N-glycosylation is caused by an increase in the activity of the cis-prenyltransferase. Biochem. J. 316(Pt 2), 575-581 (1996)
43. Mills, E.J., et al.: Primary prevention of cardiovascular mortality and events with statin treatments: A network meta-Analysis involving more than 65,000 patients. J. Am. Coll. Cardiol. 52(22), 1769-1781 (2008)
44. Haeuptle, M.A., Hulsmeier, A.J., Hennet, T.: HPLC and mass spectrometry analysis of dolichol-phosphates at the cell culture scale. Anal. Biochem. 396(1), 133-138 (2010)
45. Low, P., et al.: Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim. Biophys. Acta 1165(1), 102-109 (1992)
46. Charlton-Menys, V., Durrington, P.N.: Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. Drugs 67(1), 11-16 (2007)
47. Bergstrom, J.D., et al.: Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Annu. Rev. Microbiol. 49, 607-639 (1995)
48. Baxter, A., et al.: Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J. Biol. Chem. 267(17), 11705-11708 (1992)
49. Bergstrom, J.D., et al.: Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. U. S. A. 90(1), 80-84 (1993)
50. Chugh, A., Ray, A., Gupta, J.B.: Squalene epoxidase as hypocholesterolemic drug target revisited. Prog. Lipid Res. 42(1), 37-50 (2003)
51. Matzno, S., et al.: Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J. Lipid Res. 38(8), 1639-1648 (1997)
52. Horie, M., et al.: An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells. Biochim. Biophys. Acta 1168(1), 45-51 (1993)
53. Abe, I., et al.: Green tea polyphenols: novel and potent inhibitors of squalene epoxidase. Biochem. Biophys. Res. Commun. 268(3), 767-771 (2000)
54. Wu, A.H., et al.: Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormonal levels in healthy postmenopausal women. Cancer. Prev. Res. (Phila), (2012)